Who is sponsoring NCT02659657?

NCT02659657 is sponsored by Peking University People's Hospital.

What condition does NCT02659657 study?

NCT02659657 studies Acute Graft-versus-host Disease.

What is the status of NCT02659657?

NCT02659657 is currently UNKNOWN.

Last reviewed 2020-09-30 · How we verify

Prophylaxis Roles of Low Dose of IL-2 Treatment on GVHD After Haploidentical Transplantation

NCT02659657 Phase 2 UNKNOWN

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.

Details

Lead sponsor	Peking University People's Hospital
Phase	Phase 2
Status	UNKNOWN
Enrolment	70
Start date	2015-03
Completion	2021-12

Conditions

Acute Graft-versus-host Disease

Interventions

Interleukin-2

Primary outcomes

II-IV acute graft-versus-host disease (aGVHD) post transplantation — Day 100 post transplantation
cumultive incidence of II-IV acute graft-versus-host disease (aGVHD) post transplantation

Countries

China